Table 3.
Dosimetric results in nominal PB‐PB, PB‐MC, and MC‐MC plans of breast cancer. The results are averaged over ten breast cancer patients.
|
PB‐PB Avg. (range) |
PB‐MC Avg. (range) |
P‐value |
MC‐MC Avg. (range) |
P‐value | ||
|---|---|---|---|---|---|---|
| CTV_Total | D99% (%) | 95.5 (91.6–98.8) | 90.4 (87.9–92.6) | <0.001 | 94.1 (92.1–98.1) | 0.174 |
| D95% (%) | 97.5 (94.8–99.6) | 93.5 (91.4–95.1) | <0.001 | 97.1 (94.6–99.3) | 0.385 | |
| Dmean (%) | 100.3 (98.4–101.5) | 97.6 (95.3–98.6) | <0.001 | 100 (98.2–101.2) | 0.290 | |
| D2% (%) | 102.6 (100.2–104.3) | 101.6 (98.0–104.1) | 0.112 | 102.7 (100.1–104.6) | 0.821 | |
| Heart | Dmean (Gy(RBE)) | 0.45 (0.12–1.07) | 0.47 (0.1–0.95) | 0.762 | 0.47 (0.11–1.05) | 0.970 |
| LAD | Dmean (Gy(RBE)) | 3.37 (0.43–9.21) | 3.10 (0.43–9.06) | 0.764 | 3.64 (0.33–11.17) | 0.910 |
| Esophagus | Dmean (Gy(RBE)) | 6.02 (3.33–17.24) | 5.94 (3.63–17.53) | 0.705 | 6.28 (3.71–19.26) | 0.850 |
| Skin | Dmax (%) | 100.2 (94.6–103.1) | 101.2 (95.2–105.8) | 0.290 | 100.9 (94.8–104) | 0.406 |
| Left lung | V20 (%) | 12.4 (2.2–22.7) | 13.9 (2.6–25.3) | 0.406 | 13.1 (4.9–24.5) | 0.597 |
| Left lung | V5 (%) | 32.8 (21.6–47.5) | 37.6 (26.7–53.4) | 0.082 | 36.8 (31.1–51.9) | 0.049 |
| Right lung | V5 (%) | 1.7 (0–9.4) | 0.9 (0–4.1) | 0.597 | 1.1 (0–4.2) | 0.940 |
PB‐PB, PB optimization followed by PB dose calculation; PB‐MC, PB optimization followed by MC dose calculation; MC‐MC, MC optimization followed by MC dose calculation; CTV, clinical target volume; LAD, left anterior descending artery; RBE, relative biological effectiveness.
P‐value for PB‐MC vs. PB‐PB.
P‐value for MC‐MC vs. PB‐PB.